Treatment-resistant depression (TRD): cross-border specialty drug access for international patients

Quick orientation

Major depressive disorder affects an estimated 280 million people globally. Treatment-resistant depression (failure of at least two adequate antidepressant trials) affects approximately 30 percent of treated patients.

Typical age of onset. Adulthood; can persist for years.

Severity tiers. Severity ranges from chronic mild symptoms to severe disabling depression with suicidal ideation.

Why specialty drugs for Treatment-resistant depression (TRD) are hard to access internationally

Spravato (esketamine) and Auvelity (dextromethorphan-bupropion) represent newer mechanism classes for depression. Spravato requires REMS-style administration in qualified centers. International registration of TRD-specific labels varies.

Treatments approved by the FDA

• Spravato (esketamine nasal spray) — FDA approval: 2019. Mechanism: Non-competitive NMDA receptor antagonist. Route: Intranasal under supervised setting. US WAC ballpark: Approximately USD 30,000 to 60,000 per year. Country pricing: India · Oman · Lebanon.

Cross-border pathways used for Treatment-resistant depression (TRD)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Personal Import Scheme
• Expanded Access Program (EAP)

What your physician needs to know

• Confirm TRD diagnosis with documented prior antidepressant failures.
• Spravato requires supervised administration in qualified settings.
• Screen for substance use disorder and dissociation history.
• Psychiatrist co-management is essential.
• Concurrent oral antidepressant is required per label.

Common questions

How is Spravato administered?

Intranasal in a supervised setting due to dissociation and sedation risks.

Is it available in my country?

Registration is in select markets. We confirm by destination.

How long is treatment?

Initial induction phase followed by maintenance; duration is individualized.

Are there alternatives?

Other TRD strategies include augmentation, switching, and procedural interventions. Your psychiatrist guides the plan.

What documents are required?

Psychiatrist's prescription, prior treatment history, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Treatment-resistant depression (TRD), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Treatment-resistant depression (TRD)

Reserved for you.